Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.

Mathur BN, Neely MD, Dyllick-Brenzinger M, Tandon A, Deutch AY
Brain Res. 2007 1168: 83-9

PMID: 17706185 · PMCID: PMC2040265 · DOI:10.1016/j.brainres.2007.06.076

Proteasomal dysfunction has been suggested to contribute to the degeneration of nigrostriatal dopamine neurons in Parkinson's disease. A recent study reported that systemic treatment of rats with the proteasome inhibitor Z-lle-Glu(OtBu)-Ala-Leu-al (PSI) causes a slowly progressive degeneration of nigrostriatal dopamine neurons, the presence of inclusion bodies in dopamine neurons, and motor impairment. We examined in vitro and in vivo the effects of PSI on nigrostriatal dopamine neurons. Mass spectrometric analysis was employed to verify the authenticity of the PSI compound. PSI was non-specifically toxic to neurons in ventral mesencephalic organotypic slice cultures, indicating that impairment of proteasome function in vitro is toxic. Moreover, systemic administration of PSI transiently decreased brain proteasome activity. Systemic treatment of rats with PSI did not, however, result in any biochemical or anatomical evidence of lesions of nigrostriatal dopamine neurons, nor were any changes in locomotor activity observed. These data suggest that systemic administration of proteasome inhibitors to normal adult rats does not reliably cause an animal model of parkinsonism.

MeSH Terms (13)

Animals Animals, Newborn Corpus Striatum Cysteine Proteinase Inhibitors Dopamine Male Motor Activity Nerve Degeneration Oligopeptides Organ Culture Techniques Rats Rats, Sprague-Dawley Substantia Nigra

Connections (2)

This publication is referenced by other Labnodes entities: